The checkpoint inhibitors, anti-CTLA-4 and PD-1, are being used to maximize helper T-cell activity, first in T-cell zones to promote early B-cell recruitment and expansion and later in GCs to increase TFH activity - Current concepts in The identification and characterisation of Rho Kinase Inhibitors

The checkpoint inhibitors, anti-CTLA-4 and PD-1, are being used to maximize helper T-cell activity, first in T-cell zones to promote early B-cell recruitment and expansion and later in GCs to increase TFH activity. defined by their constitutive expression of the IL-2 receptor chain (CD25), CTLA-4, and the tumor necrosis factor (TNF)-receptor family members GITR (glucocorticoid-induced … Continue reading The checkpoint inhibitors, anti-CTLA-4 and PD-1, are being used to maximize helper T-cell activity, first in T-cell zones to promote early B-cell recruitment and expansion and later in GCs to increase TFH activity